Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Had 58 Paid Advisory Sessions on Drug Development for Startups, Academia: FY2015
April 18, 2016
- Ryukaikon Agrees on Mandatory Barcode Labeling by March 2021; March 2022 for Exceptions
April 18, 2016
- Quake Brings Production Offline at 1 Out of 24 Firms in Affected Region: MHLW
April 18, 2016
- Promoting Use of Patient Registries Important in Building Clinical Innovation Network: Health Policy Bureau Chief
April 18, 2016
- Dyslipidemia Risk Triples in Patients on Olanzapine: PMDA Epidemiology Study
April 15, 2016
- Expedited Review Systems Now in Place in 3 Major Markets, but How Are They Different?
April 15, 2016
- LDP Proposal for New Growth Strategy to Push “Clinical Innovation Network”
April 15, 2016
- New Scheme on Switch OTC Gets Underway
April 14, 2016
- MHLW to Issue Notification to Ensure Restricted Use of Repatha
April 14, 2016
- Indication-Based Front-Loaded Re-Pricing, Coverage Limits Emerge for Pricey Meds: Chuikyo
April 14, 2016
- Chuikyo to Make Go or No-Go Decision on Drug Price Survey by Mid-2016
April 14, 2016
- MHLW Panels Approve Guidelines for Reporting Adverse Reactions to Hep B Vaccines
April 14, 2016
- Govt, Industry Agree to Boost Public-Private Policy “Dialogue” to Deepen Talks on Social Security Challenges
April 13, 2016
- Chuikyo OKs Repatha for NHI Price Listing on April 20, Peak Sales Projected at 49 Billion Yen
April 13, 2016
- MHLW Advisory Panel to Discuss Ono’s Cancer Drug Carfilzomib on April 25
April 12, 2016
- With Eyes on Pricey Meds, Cost-Shaving Debate Unabated Despite Likely Tax Hike Delay
April 11, 2016
- Centralized Support Unit Needed for “Clinical Innovation Network”: JPMA’s Teshirogi
April 8, 2016
- PMDA to Set Up Hokuriku Branch to Train Asian Regulators
April 8, 2016
- Editor’s Pick: Five Healthcare Policy News Headlines for March
April 8, 2016
- MHLW Advisory Panel to Discuss Nobelpharma’s Epilepsy Drug on April 20
April 8, 2016
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…